Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma

PHASE2UnknownINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

June 30, 2019

Study Completion Date

December 31, 2021

Conditions
Thymic CarcinomaThymus NeoplasmsThymus Cancer
Interventions
DRUG

Pembrolizumab

Administration of 200 mg MK-3475 once every 3 weeks

DRUG

Epacadostat

100mg taken by mouth twice daily

Trial Locations (1)

20007

Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Incyte Corporation

INDUSTRY

lead

Georgetown University

OTHER